SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial potential ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited takeover has now passed, and in the absence of clear ...

January 27, 2025 Sage rejects Biogen's $469 million takeover offer, says offer undervalues company Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million ...

As the Cambridge drugmaker contemplates its future, the biotech’s chief medical officer has become the latest executive to exit the company. As Sage Therapeutics Inc. contemplates its path ...

Sage Therapeutics and partner Biogen equally shares profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...

Biotechnology company Biogen (BIIB) announced on Monday plans for new headquarters at Kendall Common, located at 75 Broadway ...

Biogen Inc. plans to move its headquarters into a 16-story Kendall Square tower to be developed by MIT and BioMed Realty ...

Bullish option flow detected in Biogen (BIIB) with 2,556 calls trading, 1.5x expected, and implied vol increasing over 1 point to 34.69%.